These data support clinically meaningful efficacy within this patient population. We observed a high rate of complete responses in patients with laCSCC
Clears major obesity endpoints at 80 weeks
The ruling brings closure to a nearly decade-long investigation into hospital operations and healthcare delivery practices
All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks
This positions its platform as a rapidly evolving engine for next-generation genetic medicine
Medanta expanded its bed capacity by 20% during the year
The study has shown that perioperative treatment with Imfinzi (durvalumab), alone or in combination with other immunotherapy agents
Nearly one in five women worldwide are now living with obesity
The twin designations are designed to speed up the development and review of promising medicines targeting serious conditions with high unmet need
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
